Hammermeldung!!! $$$$$$!!!! Sensationell für diese Aktie. - 500 Beiträge pro Seite

[holle72]

Darauf haben wir gewartet: Die Meldung:

Generex Biotechnology Announces U.S. Distribution of New Glucose Rapidspray(TM) Product
E-mail or Print this story
18 September 2006, 09:50am ET

Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that Cardinal Health will distribute its new Glucose RapidSpray(TM) product in the U.S.

Glucose RapidSpray is expected to be in stores by October, 2006.

Glucose RapidSpray is an innovative alternative for people who require or want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation that was developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray delivers glucose directly into the mouth where the proprietary formulation is rapidly absorbed into the blood stream. Glucose RapidSpray is simple to carry and use, with no large tablets to chew or messy gels to swallow.

"Using our patented technology -- RapidMist(TM) -- we've developed a product that will deliver glucose to anyone who needs a fast and efficient means for receiving glucose," said Anna Gluskin, President & Chief Executive Officer of Generex. "We expect that Glucose RapidSpray will appeal to people battling the symptoms of low blood sugar who now use other over-the-counter glucose products but want a faster-acting product. We expect to position Glucose RapidSpray as a companion product to Generex Oral-lyn(TM), our proprietary oral insulin spray product, in the diabetes management field."

About Generex

Mentioned Last Change
GNBT 1.71 (Unchanged)
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

[HerMitDerMillion]

Heute geht's ab!

SK in USA: 1,72 USD bei hohem Volumen
Entspricht 1,35 EUR!

[holle72]

Antwort auf Beitrag Nr.: 24.034.568 von HerMitDerMillion am 19.09.06 08:28:37

Das ist aber nur der Anfang gewesen. Kaufen!

[CK2004]

Antwort auf Beitrag Nr.: 24.034.736 von holle72 am 19.09.06 08:40:48

Leute kauft - schließlich leben einige von dem Verkauf von Aktien.
Die Firma selbst macht kaum Umsätze aber konstant Verluste in Millionenhöhe!

http://finance.yahoo.com/q/is?s=GNBT&annual

[holle72]

Das ist bei sochen Aktien nun mal. Das die erst mal Verluste machen, ist in der Branche mehr als normal, aber wie gesagt, wir können auf Dich durchaus verzichten. Ein ganz klarer Kauf.

[CK2004]

Antwort auf Beitrag Nr.: 24.034.823 von holle72 am 19.09.06 08:50:23

Und wir können auf deine Supertipps verzichten!

Du suchst doch nur Idioten die dir deine Aktien zu einem höheren Preis abkaufen!

[CK2004]

Antwort auf Beitrag Nr.: 24.034.857 von CK2004 am 19.09.06 08:53:46

Sorry, ich nehme alles zurück!
Ist eine seriöse Firma - siehe Aktionärskreis!

http://finance.yahoo.com/q/mh?s=GNBT

[Kalle.gr]

Antwort auf Beitrag Nr.: 24.034.432 von holle72 am 19.09.06 08:19:13

noch ein Thread zu dieser Aktie, na ihr scheint es ja nötig zu haben.

[holle72]

Antwort auf Beitrag Nr.: 24.035.185 von Kalle.gr am 19.09.06 09:12:01

Man kann lesen, daß du überhaupt keine Ahnung hast und auch noch unverschämt den Leuten gegenüber bist, die ein Problem mit Diabetes haben. Diese Zahl wird in den nächsten Jahren leider zunehmen. Hirnverbrannt deine Aussage. Müsste eigentlich gesperrt werden. Diese Aktie verdient damit Geld und es ist gut, daß es so eine Firma gibt. Kalle, schäm Dich. Mein ich wirklich ernst!!!